Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate
A Phase 2, Multi-center, Randomized, Double Blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy
Sponsor: Lexicon Pharmaceuticals
Listed as NCT00903383, this PHASE2 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Lexicon Pharmaceuticals, it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lexicon Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Belgrade, Serbia , Bialystok, Poland , Bruntál, Czechia , Budapest, Hungary , Békéscsaba, Hungary , Cumberland, United States , Dallas, United States , Działdowo, Poland , Flowood, United States , Gainesville, United States and 28 more locations